1. Home
  2. MLYS vs STC Comparison

MLYS vs STC Comparison

Compare MLYS & STC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$25.03

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Stewart Information Services Corporation

STC

Stewart Information Services Corporation

HOLD

Current Price

$65.44

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLYS
STC
Founded
2019
1893
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2023
1994

Fundamental Metrics

Financial Performance
Metric
MLYS
STC
Price
$25.03
$65.44
Analyst Decision
Strong Buy
Buy
Analyst Count
7
3
Target Price
$48.67
$81.00
AVG Volume (30 Days)
1.9M
136.8K
Earning Date
05-06-2026
04-22-2026
Dividend Yield
N/A
3.00%
EPS Growth
37.43
55.17
EPS
N/A
0.55
Revenue
N/A
$2,921,636,000.00
Revenue This Year
N/A
$13.62
Revenue Next Year
N/A
$7.13
P/E Ratio
N/A
$120.16
Revenue Growth
N/A
17.32
52 Week Low
$12.59
$56.39
52 Week High
$47.65
$78.61

Technical Indicators

Market Signals
Indicator
MLYS
STC
Relative Strength Index (RSI) 44.59 46.55
Support Level $22.36 $62.45
Resistance Level $31.29 $66.92
Average True Range (ATR) 1.43 1.65
MACD -0.22 0.08
Stochastic Oscillator 28.15 51.83

Price Performance

Historical Comparison
MLYS
STC

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments: Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

Share on Social Networks: